Therapeutic Areas
Patient-Centric Innovation for Unmet Medical Needs
-
Metabolism & Endocrinology
Leveraging sustained-release peptides and multifunctional molecules to deliver safe, accessible therapies.
Learn More -
Immunology & Respiratory
We are committed to delivering breakthrough therapies for immune-related diseases across rheumatology, dermatology, gastroenterology, respiratory, renal, and neurology.
Learn More -
Ophthalmology
Leveraging core inflammatory and endocrine mechanisms to expand treatment options for ocular diseases.
Learn More -
Oncology
Delivering new options that extend and improve the lives of people living with cancer.
Learn More -
Women's Health
Delivering both hormonal and non-hormonal therapies for every stage of a woman's journey—from IVF through obstetrics and gynecology.
Learn More
RESEARCH AND DEVELOPMENT
Sustaining Innovation...
-
30+
Marketed Products
-
40+
Pipeline
-
26.5%
R&D investment
(% of 2025 revenue)
To challenge, create, and push the boundaries of possibility.
Latest News
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2026-06-24
GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious PubertyLearn More
-
2026-06-04
GenSci: Two Innovations Granted IND Clearance by FDALearn More